If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Global Fc and Glycoengineered Antibodies Market Size
The global Fc and glycoengineered antibodies market is estimated to be worth US$ 38.8 billion in 2024. Driven by the increasing potential of these engineered antibodies as therapeutic agents, the market is anticipated to grow at a notable rate during the forecast period. Further, in terms of type of engineering, Fc engineered antibodies are likely to capture majority (93%) of the share, followed by glycoengineered antibodies (7%) within the overall market, by 2035.
Frequently Asked Questions
Question 1: What is Fc region engineered antibodies?
Answer: Engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, are termed as Fc region engineered antibodies. The modifications in the Fc region of an antibody have been shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Question 2: How big is the Fc and glycoengineered antibodies market?
Answer: The Fc and glycoengineered antibodies market size is anticipated to be worth $38.8 billion in 2024.
Question 3: Who are the leading players developing Fc and glycoengineered antibodies?
Answer: Examples of key companies engaged in Fc and glycoengineered antibodies industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, Akesobio, Alexion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, MacroGenics, MorphoSys, Kyowa Kirin and Xencor.
Question 4: How many Fc and glycoengineered antibodies are currently marketed?
Answer: Around 20 Fc and glycoengineered antibodies are currently marketed across different therapeutic indications.
Question 5: How many companies are currently engaged in the Fc and glycoengineered antibodies market?
Answer: Over 30 companies are currently engaged in the Fc and glycoengineered antibodies industry.
Question 6: Which type of engineering are mainly used to develop Fc and glycoengineered antibodies by various developers?
Answer: At present, majority (93%) of the developers are using Fc engineering to develop Fc and glycoengineered antibodies.
Question 7: Which type of therapy is popular for the development of different Fc and glycoengineered antibodies?
Answer: In the realm of Fc and glycoengineered antibodies, monotherapies are mainly focused, sharing 46% share in the current market.
Question 8: Which target therapeutic area occupies the largest market share of the Fc and glycoengineered antibodies market?
Answer: In 2024, oncological disorders has the largest market share (39%) of the Fc and glycoengineered antibodies market.
Question 9: What is the most common route of administration used for Fc and glycoengineered antibodies?
Answer: Currently, intravenous rou
Https://www.independent.co.uk/news/health/covid-vaccine-research-pandemic-uk-b2539136.html
Chelsea what’s the score on this post.?
We only have one commercial deal and it’s with Genmab on the Glymab platform. Ld has said someone might want exclusivity! We know there is also interest in them taking another Glymab as they are “happy “ with the one that they have
Chelsea I would like to see some of your research on why it’s not relevant as a counter argument?
How many arrows in the quiver ? All for 9 p
https://amp.theguardian.com/society/article/2024/may/06/scientists-create-vaccine-potential-protect-against-future-coronaviruses
Scientists have created a vaccine that has the potential to protect against a broad range of coronaviruses, including varieties that are not yet even known about.
Still in mice !
Hey Ian Sample your behind on news it’s been done before ? Does anyone know how to email him ?
Covidity the link
COVIDITY - Scancell
The first in human (FIH) study is designed to explore the safety, tolerability, and immunogenicity of COVIDITY in healthy adults when administered by needle-free injection. Further information can be found here - A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
Texas Biomed partners with Scancell to test novel COVID vaccine - Texas Biomed
SAN ANTONIO (Aug. 29, 2023) – A DNA-based vaccine is very effective at protecting against COVID-19, according to a joint preclinical study by Scancell Ltd and Texas Biomedical Research Institute (Texas Biomed) recently published in the Journal of Biotechnology and Biomedicine.
Unlike the Pfizer and Moderna COVID-19 vaccines that use messenger RNA (mRNA) to cue the immune system to produce antibodies, this vaccine platform uses sections of viral DNA to achieve a similar result.
“There is always a need to develop new, or improve on existing vaccines to ensure we have effective tools to counter emerging variants,” says Texas Biomed Innovation Lab Principal Investigator Viraj Kulkarni, PhD. “DNA vaccines are one of the promising alternatives because they are adaptable, simple to generate and effective.”
Also this is the other role
Director, Legal Counsel (US Market Operations)
Your job will include reviewing, drafting and negotiating agreements for the Market Operations Team, be part of the cross functional group reviewing commercial and scientific materials, provide relevant legal training to sales representatives and others, and provide legal support regarding various types of contracts and engagements
*
* Responsible for legal review of scientific and commercial/marketing material for use in the US Market in close cooperation with Genmab colleagues but also with Genmab collaboration partners.
* Support Marketing and Sales with negotiation, drafting and/or review of commercial agreements
Support Medical Affairs with negotiation, drafting and/or review of agreements (e.g., Advisory Boards) and provide legal review of scientific materials
* Support Market Access by providing legal advice relating to patient support programs, and drafting/ reviewing of applicable agreements (e.g., with service providers for various patient support programs), and providing legal advice relating to arrangements and agreements with various entities in the health care delivery system (including payers, specialty distributors/distributors, GPOs and health care providers and institutions)
Looks like Genmab beefing up legal teams in USA .
Their KYO time line seems to be working
We also know close relationship with Scancell noted LD was tight lipped
Good posts this morning from
Chill time over on the other side
From jobs
https://www.goinhouse.com
After it announced this week
Director, Legal Counsel (US Market Operations)
* Genmab
* Princeton, NJ
Apr 23
* Director, Patent Attorney
* Genmab
* Princeton, NJ
Apr 15
Recent Genmab news
May 2, 2024 at 5:02 PM CEST
Genmab Announces Financial Results for the First Quarter of 2024
Download
Apr 30, 2024 at 12:40 AM CEST
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29, 2024 at 10:24 AM CEST
Transactions in Connection with Share Buy-back Program Genmab
Download
Download
Kate Bingham tells NHS to launch experimental cancer vaccine trials with pioneering technology that trains the immune system how to hunt malignant cells
https://www.dailymail.co.uk/health/article-13383755/Former-Covid-jab-tsar-tells-NHS-launch-experimental-cancer-vaccine-trials-pioneering-technology-trains-immune-hunt-malignant-cells.html
“Dr Lennard Lee, a cancer vaccine expert at the University of Oxford, said there are now 12 drug manufacturers testing cancer jabs in the UK. He added: 'We are already gaining the reputation as the best country in the world to develop cancer vaccines.'
This was a post on linked in from a month ago
Robert Watson
•
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
1mo •
From a month ago F
Fascinating to attend an investigator meeting for Scancell Ltd's SCOPE study - the second meeting for a
hashtag
#cancervaccine clinical trial in melanoma that I've been to in the space of a few weeks. Great to hear about the immunology underpinning the therapy and enjoyable to interact with other trial teams around the UK. It is really fantastic to be able to offer these cutting-edge clinical trials to our patients at Oxford University Hospitals NHS Foundation Trust and see such rapid ongoing progress in the cancer vaccine space.
Having just read the article posted in the times . its interesting the derisory share price of Scancell , will hopefully be a thing of the past when data arrives
It takes an American Biotech expert to showcase the company and a very confident Lindy Durrant
we just need more "patience and patients" to put the data forward
Good morning
positive interview and a confident Lindy Durant
1 the new improved vaccine it’s going to mean that it’s available for everybody . More people all types (4 already ) so fast into the clinic bigger numbers .does that translate into Fast track approval!
2 Madonna as being personalised is a juggernaut it’s expensive ,not going to be available for
3. The main listing is interesting because maybe some sort of share swop / takeover? Nasdaq in the next breath . A nod to us the long term holders AIM has been good to us
4 I think you should also listen to the prof Christian ottenmeiser 7 mins in
5. Also post re melanoma month and Scancell post on stuff coming out ? Patients on trials maybe
Christian ottenmeiser on news the day all the Moderna publicity was out ? Does anyone think this could be Moditope , moderna , scope either was his take on personal vaccines is interesting ?
8 minutes in v interesting
https://www.youtube.com/watch?v=eToDmmja2xk
Https://www.google.com/search?q=Radio+5+Live+interview+-+cancer+vaccine+research+at+The+Clatter...&ie=UTF-8&oe=UTF-8&hl=en-gb&client=safari#fpstate=ive&vld=cid:0c330470,vid:eToDmmja2xk,st:0
Thanks for your kind words Balerno2 as you look into what I post . May I share this
Christian ottenmeiser
8 minutes in v interesting interview with Christian Ottenmeiser 26 th of April the time the news was buzzing with Moderna
( everyone missed I pointed out the Times changes it’s headline to “bespoke vaccine “ from I think hard to treat melanoma “
Christian ottenmeiser , Sarah Danson and heather shaw are all involved in some chief investigative capacity with the current Scancell trials
Would like your opinion Balernio ? Have a good listen
I consider the upstart Scancell under prof Lindy Durrant were always fire runners
youtube.comBBC Radio 5 Live interview - cancer vaccine research at The Clatter...
The Great National Cancer Vaccine Summit.
This was yesterday.
The agenda
Heather shaw , Kate Bingham , Christian ottenmeiser
Great line up
https://www.convenzis.co.uk/events/the-great-national-cancer-vaccine-summit#eventagenda
https://www.convenzis.co.uk/events/the-great-national-cancer-vaccine-summit
We welcomed delegates from industry, government, public sector, academia, research system, and of course healthcare.
We delved into the intricacies of the incredible national cancer vaccine advance that has recently captured the publics imagination.
Brad Loncar , has started his tour of the uk Biotech
He is an astute man . Imagine it’s well researched and he is interested to hear what Lindy has to say ? As we all are .
See below GSK ( results were out today )
TOP VIDEO: GSK's Emma Walmsley on the company's pipeline, business development, AI, UK life sciences, and more | 04/30/24
https://www.biotechtv.com
Excellent
I thought, would have at the vaccines we have pitched against in the other trials in the ASCO article find below
1.Evaxion Biotech 26th of April -4.1800
+0.0600 (+1.46%)
Day's Range 4.0500 - 4.2500
52 Week Range 2.8240 - 18.5000
https://www.evaxion-biotech.com
2. BioNtech https://www.biontech.com/int/en/home.html
Prev. Close 86.71
52 Wk. Low 85.21
52 Wk. High 125.83
3. Moderna https://www.modernatx.com/en-GB
Prev. Close 106.18
52 Wk. Low 62.55
52 Wk. High 142.79
4. Scancell https://www.scancell.co.uk
Prev. Close 9.60p
52 Wk. Low 7.59
52 Wk. High 18.29
5.IQ Biotech, Inc
https://iobiotech.com
Prev. Close 1.4500
52 Wk. Low 0.8160
52 Wk. High 2.6400
ASCO PUBLICATIONS
26th of April
“Curing Stage IV Melanoma: Where Have We Been and Where Are We?”
https://ascopubs.org/doi/10.1200/EDBK_438654
scroll down to Cancer Vaccines :
BioNTech (BNT221),57 while Moderna is focusing on the adjuvant melanoma space in collaboration with Merck.58 BioNTech is also the manufacturer of BNT111, a cancer vaccine encoding for a fixed set of four cancer-specific antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE),59 now being evaluated combined with cemiplimab in a randomized prospective trial that has recently completed recruitment (ClinicalTrials.gov identifier: NCT04526899).
Other innovative vaccine approaches in testing include Scancell's DNA plasmid vaccine, SCIB1, which incorporates specific epitopes from proteins gp100 and TRP-2, identified from the cloning of T cells from patients who spontaneously recovered from melanoma. Both proteins play key roles in the production of melanin. Evaluation of the first 12 patients recruited to a phase II trial combining SCIB1 with ipinivo reported a response rate of 83% (ClinicalTrials.gov identifier: NCT04079166). IO102-IO103, manufactured by IO Biotech, targets immunosuppressive proteins such as IDO and PD-L1. The phase I/II trial (KEYNOTE-D18) combined with pembrolizumab and demonstrated an overall response rate of 73% and a CR rate of 47%. These results led to the FDA granting breakthrough designation of the combination, and a confirmatory randomized phase II trial is underway (ClinicalTrials.gov identifier: NCT05280314).
Thanks for clearing that up Bermuda
Good find WTP
the 26 th of April The good law project are questioning Sunak relationship with his fund Thelme and Moderna. A £400,000 Bespoke vaccine per patient ( as the times are now calling it ) a 10 year contract / tie in with the NHS is questionable ? belt and braces measure, after surgery . So how much is the total cost ? tIt’s a very interesting debate. Please read this link.
https://goodlawproject.org/government-ordered-to-disclose-sunaks-hedge-fund-emails/#:~:text=Shortly%20after%20Sunak%20became%20prime,a%20financial%20interest%20in%20Theleme.